Immune checkpoint inhibitors associated interstitial lung diseases (ICI-ILD) affect approximately 2-5% of patients receiving immunotherapy and represent one of the most serious and potentially life-threatening immune-related adverse events. The pathogenesis re... ...

请注册登录后继续浏览